Xbrane Biopharma AB, adopted at the Annual General Meeting on May 4, 2023, The nomination committee, which shall be appointed for the time until a new nomination committee has been appointed, shall consist of three members, whom shall be nominated by the Company?s three largest shareholders with respect to voting power as per 30 September 2023. Based on the above, the Nomination Committee for the AGM in 2024 has been set up to consist of the following, which together represent approximately 25% of the number of shares and votes in the Company as of September 30, 2023: Ashkan Pouya, appointed by Serendipity Group AB, the Company´s largest shareholder, Bengt Göran Westman, the Company´s second largest shareholder; Oscar Bergman appointed by Swedbank Robur Fonder, the Company´s third largest shareholder; Anders Tullgren, Chairman of the Company co-opted member.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.234 SEK | +5.88% |
|
-13.33% | -97.66% |
May. 22 | Xbrane Successfully Scale Up Xdivane- Biosimilar Candidate to Opdivo®? | CI |
May. 16 | Transcript : Xbrane Biopharma AB, Q1 2024 Earnings Call, May 16, 2024 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-97.66% | 33.98M | |
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B |
- Stock Market
- Equities
- XBRANE Stock
- News Xbrane Biopharma AB
- Xbrane Biopharma AB Presents Nomination Committee